Rapid exacerbation of neuromyelitis optica after rituximab treatment
Dai, Y., Lu, T., Wang, Y., Fang, L., Li, R., Kermode, A.G. and Qiu, W. (2016) Rapid exacerbation of neuromyelitis optica after rituximab treatment. Journal of Clinical Neuroscience, 26 . pp. 168-170.
*Subscription may be required
Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.
|Publication Type:||Journal Article|
|Murdoch Affiliation:||Institute for Immunology and Infectious Diseases|
|Copyright:||© 2016 Elsevier B.V.|
|Item Control Page|